



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 28th September 2020

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Zoom. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda for December 2020.

3. Matters Arising

The Group noted the matters arising from the previous meeting. Following presentation of a summary - Melatonin 1mg & 5mg Prolonged-Release Tablets (Sleynto[®]) to be added to the Trust Formulary for use in Paediatrics.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- Nil

Ex-panel

- Nil

Removals

- Nil

NICE Approved drug applications

Approved by the Pharmacoeconomic Board on 23/07
Outcome: Noted

- **IVIg for Paraneoplastic Neuropathy**

Approved by the Pharmacoeconomic Board on 24/07
Outcome: Noted

- **Vedolizumab for Ulcerative Colitis**

Approved by the Pharmacoeconomic Board on 28/07
Outcome: Noted

- **Ibalizumab for MDR HIV**

Approved by the Pharmacoeconomic Board on 30/07
Outcome: Noted

- **Pembrolizumab for Relapsed Small Cell Prostate Cancer**

Approved by the Pharmacoeconomic Board on 12/08
Outcome: Noted

- **Pembrolizumab for PML**

Approved by the Pharmacoeconomic Board on 11/09
Outcome: Noted

4.2 Trust Medicines Policy



- **TMP: Section 1: Introduction**

- Full review and update
- Addition of:
 - Medicines Optimisation Steering Group reporting to Trust Medicines Group
 - Organogram for Pharmacy Governance Structure
- Removal of:
 - Reference to the Immunoglobulin Approval Panel as this has been replaced by the North West London Sub Regional Immunoglobulin Approval Panel.

Outcome: Approved

- **TMP - Section 16: Ward/Department openings and closings**

- Full review and update
- Addition:
 - Need to remove all stock medicines from the refrigerator during a temporary closure.

Outcome: Approved

- **TMP - Section 19: The Formulary**

- Full review and update
- Addition of:
 - Section relating to licensing of medicines in Section 19.3
 - Review of applications for Antiretrovirals by the Clinical Directorate of HIV and GUM, Medicines Sub-Group
 - Pharmacoeconomic Board members contact details

Outcome: Approved

4.3 Medicines Optimisation

- **Convulsive Status Epilepticus in Adults - In-patient Management**

The aim of this guideline is to provide healthcare professionals, including those working in Accident and Emergency and on in-patient wards, with the recommended practice for management of adult patients in Convulsive Status Epilepticus

Outcome: Approved

- **Hospital Pharmacy Transformation Plan - Update**

The '**Leading Integrated Pharmacy and Medicines Optimisation**' (IPMO) guidance' was published on Wednesday 23rd of September. This document sets out the principles and approach to the development of a pharmacy and medicines optimisation transformation plan in each Integrated Care System (ICS) and a system-wide pharmacy professional leadership model to bring about collective management of system performance.

Hospital Chief Pharmacists are asked to work with their respective Regional Chief Pharmacist to implement the IPMO guidance

DL had already started work on reviewing and updating the current Trust Medicines Optimisation Strategy and Trust Hospital Pharmacy Transformation Plan, however this now needs to be paused to work on a collaborative ICS/STP approach.

For that reason DL has requested that the expiries on the *Trust Medicines Optimisation Strategy* and *Trust Hospital Pharmacy Transformation Plan* are extended to 30/11/2020, to allow time for the STP/ICS document(s) to be developed and approved. This request of extension has been approved by the Trust Medical Director.

Outcome: Noted

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

1 Appraisal published in June 2020



5 Appraisals published in August 2020
4 Appraisals published in September 2020

TA640 - Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
Formulary status / Action
Nil action - Not applicable - CWFT not commissioned

TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Formulary status / Action
Currently included on the formulary for other indication.
Numbers likely to treat at CWH site: 1-2 patients per year
Numbers likely to treat at WMUH site: 3 patients per year

TA642 - Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Formulary status / Action
Nil action - Not applicable - CWFT not commissioned

TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Formulary status / Action
Add to the formulary following receipt of a signed application form from the CW Oncology Team.

TA644 - Entrectinib for treating NTRK fusion-positive solid tumours
Formulary status / Action
Add to the formulary following receipt of a signed application form from the Oncology Team.

TA645 - Avelumab with axitinib for untreated advanced renal cell carcinoma
Formulary status / Action
Nil action - Not applicable - CWFT not commissioned

TA646 - Glasdegib with chemotherapy for untreated acute myeloid leukaemia (Terminated appraisal)
Formulary status / Action
Nil - Terminated appraisal

TA647 - Eculizumab for treating relapsing neuromyelitis optica (Terminated appraisal)
Formulary status / Action
Nil - Terminated appraisal

TA648 - Dupilumab for treating chronic rhinosinusitis with nasal polyps (Terminated appraisal)
Formulary status / Action
Nil - Terminated appraisal

a) **NICE Highly Specialised Technologies published since last meeting**
0 Highly Specialised Technologies published

b) **Update on NICE TA617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (8 January 2020)**

Noted at January 2020 TMG meeting as "Nil action - Not applicable - CWFT not commissioned". However, it has been confirmed that the Commissioner for Lusutrombopag will be the CCGs. The CCGs will commission



PbR ex drugs prescribed in line with the NICE TA once it has approved by the TMG and added to the local Formulary.

Formulary status / Action

Add to the formulary following receipt of a signed application form from the Hepatology Team.

4.5 IVIG requests

• **IVIG Issues for July 2020 - CWH Site**

There were 4 IVIG issues in July 2020, with 2 new requests:

Outcome: Noted

• **IVIG Issues for July 2020 - WMUH Site**

There were 9 IVIG issues in July 2020, with 3 new requests:

Outcome: Noted

• **IVIG Issues for August 2020 - CWH Site**

There were 6 IVIG issues in August 2020, with 2 new requests:

Outcome: Noted

• **IVIG Issues for August 2020 - WMUH Site**

There were 8 IVIG issues in August 2020, with 2 new request

Outcome: Noted

4.6 Items for noting

• **Quarterly Controlled Drug Summary Report - Q1 2020/21**

Quarterly Controlled Drug Summary Report for Q1 2020/21

Outcome: Noted

• **Quarterly Controlled Drugs Accountable Officer Report - Q1 2020/21**

Quarterly CD Accountable Officer Report for Q1 2020/21

Outcome: Noted

• **Patient Safety Group Report- September 2020**

Patient Safety Group report covering June-August 2020

Outcome: Noted

• **Medication Safety Bulletin - Controlled Drug Discrepancies**

Medication safety Bulletin relating to Controlled Drug Discrepancies - Published August 2020

Outcome: Noted

• **Medication Safety Bulletin - Lessons learned from a Look-Alike Medicines incident**

Medication safety Bulletin relating to Lessons learned from a Look-Alike Medicines incident - Published September 2020

Outcome: Noted

• **MHRA Drug Safety Update - July 2020**

MHRA update for July 2020

Outcome: Noted

• **MHRA Drug Safety Update - August 2020**

MHRA update for August 2020

Outcome: Noted

4.7 Meeting minutes for noting



- **Antibiotic Steering Group - July 2020**

Minutes from Antibiotic Steering Group meeting - July 2020

Outcome: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - August 2020**

Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - August 2020

Outcome: Noted

4.8 Additional papers to go to Trust Patient Safety Group

- Nil

5. Any other business

- Human Papillomavirus 9-Valent Vaccine (Gardasil 9®)

Action: DR to follow-up progress with OH

- Consultation in NWL CCG

Outcome: Noted

- Vitamin B preparations

Action: DR to follow-up with Lead Directorate Pharmacist - Medicine

6. Date of next meeting

Date: 2nd November

Time: 8am-9am

Location: Via Zoom

Closing date: 16th October 2020